Journal of Biomaterials
Volume 3, Issue 1, June 2019, Pages: 24-27
Received: Apr. 16, 2019;
Accepted: Jun. 18, 2019;
Published: Jul. 2, 2019
Views 153 Downloads 39
Kazuyoshi Kaminaka, Development Department, KM Biologics Co., Ltd., Kumamoto, Japan
Chikateru Nozaki, Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan
Vaccines have greatly contributed to the prevention of infectious diseases. Most current vaccines are inoculated by intramuscular or subcutaneous injection using syringes. These inoculation methods involve pain, bleeding, fear, needlestick accidents. One promising method that can overcome these disadvantages is vaccination using microneedles. MN materials are already FDA-approved for implantation or parenteral delivery for other applications. MNs can increase the transdermal permeability and deliver vaccine compounds including proteins, genetic materials and so on. There are several types of microneedles. Among them, a number of research and development has been carried out on coated MN and dissolving MN. The surface of coated MN is coated with the vaccine. On inserting into the skin, the vaccine is directly deposited into the epidermis or the upper dermis layer. Dissolving MNs are fabricated with biodegradable polymers by encapsulating the vaccine into the polymer. After inserting dissolving MN into the skin, dissolution takes place which releases the vaccine. Conventional influenza vaccines and universal vaccine candidates have been shown to be delivered to the body using MN and to have effective immunogenicity. DNA vaccines are simple to induce both of cellular and humoral immune response that make them attractive vaccine candidates. A disadvantage of DNA vaccines is their poor immunogenicity in intramuscular administration. Hepatitis B virus DNA has been shown to induce effective immunity by administration using MN with an adjuvant. This review introduces concrete works for microneedle vaccines against influenza and hepatitis B.
Microneedle: Effective Means for Vaccination, Journal of Biomaterials.
Vol. 3, No. 1,
2019, pp. 24-27.
Wysocki AB. Skin anatomy, physiology, and pathophysiology. Nurs Clin North Am 1999; 34 (4): 777-97.
Bos JD, and Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000; 9 (3): 165-9.
Chuong CM, Nickoloff BJ, Elias PM, What is the 'true' function of skin? Exp Dermatol 2002; 11 (2): 159-87.
Tobin DJ. Biochemistry of human skin–our brain on the outside. Chem Soc Rev 2006; 35 (1): 52-67.
Kenney RT, Yu J, Guebre-Xabier M, Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 2004; 190 (4): 774-82.
Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012; 64 (14): 1547-68.
Pérennès F, Marmiroli B, Matteucci M, Tormen M, Vaccari L, Di Fabrizio E. Sharp beveled tip hollow microneedle arrays fabricated by LIGA and 3D soft lithography with polyvinyl alcohol. Journal of Micromechanics and Microengineering. 16 (2006), pp. 473-479.
Yoon YK, Park JH, and Allen MG. Multidirectional UV lithography for complex 3-D MEMS structures. Journal of Microelectromechanical Systems. 15 (5) (2006): pp. 1121-1130.
Migdadi EM, Courtenay AJ, Tekko IA, McCrudden MTC, Kearney MC, McAlister E, McCarthy HO, Donnelly RF. Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride. J Control Release. 2018 Sep 10; 285: 142-151.
Cheung K, Das DB. Microneedles for drug delivery: trends and progress, Drug Deliv. 2016; 23 (7): 2338-2354.
Chen B, Wei J, Tay F, Wong Y, Iliescu C. Silicon Microneedle array with biodegradable tips for transdermal drug delivery. Microsystem Technologies 14 (7) (2008), pp. 1015-1019.
Chen BZ, Ashfaq M, Zhang XP, Zhang JN, and Guo XD. In vitro and in vivo assessment of polymer microneedles for controlled transdermal drug delivery. J Drug Target. 2018; 26 (8): 720-729.
Fernando GJP, Hickling J, Jayashi Flores CM, Griffin P, Anderson CD, Skinner SR, Davies C, Witham K, Pryor M, Bodle J, Rockman S, Frazer IH, Forster AH. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine. 2018; 36 (26): 3779-3788.
Zhu W, Li S, Wang C, Yu G, Prausnitz MR, Wang BZ. Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch. Front Immunol. 2018; 9: 1705.
Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: Shifting to better vaccines. Vaccine. 2016; 34 (26): 2926-2933.
Farahmand B, Taheri N, Shokouhi H, Soleimanjahi H, Fotouhi F. Chimeric protein consisting of 3M2e and HSP as a universal influenza vaccine candidate: from in silico analysis to preliminary evaluation. Virus Genes. 2019; 55 (1): 22-32.
Liu MA. DNA vaccines: an historical perspective and view to the future. Immunological reviews. 2011; 239 (1): 62–84.
Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2016; 15 (3): 313-29.
Hobernik D, Bros M. DNA Vaccines-How Far From Clinical Use? Int J Mol Sci. 2018; 19 (11). pii: E3605.
Qiu Y, Guo L, Zhang S, Xu B, Gao Y, Hu Y, Hou J, Bai B, Shen H, Mao P. DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN. Drug Deliv. 2016; 23 (7): 2391-2398.
Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccine. 2011; 10 (4): 499–511.
Guo L, Chen J, Qiu Y, Zhang S, Xu B, Gao Y. Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant. Int J Pharm. 2013; 447 (1-2): 22-30.